Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.
Identifieur interne : 000091 ( PubMed/Curation ); précédent : 000090; suivant : 000092Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.
Auteurs : Fred Stephen Sarfo [Ghana] ; Adetayo Kasim [Royaume-Uni] ; Richard Phillips [Ghana] ; Anna Maria Geretti [Royaume-Uni] ; David R. Chadwick [Royaume-Uni]Source :
- The Journal of infection [ 1532-2742 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (effets indésirables), Agents antiVIH (usage thérapeutique), Co-infection, Facteurs temps, Femelle, Foie (), Ghana, Humains, Hépatite B (), Hépatite B (immunologie), Infections à VIH (), Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active (effets indésirables).
- MESH :
- effets indésirables : Agents antiVIH, Thérapie antirétrovirale hautement active.
- immunologie : Hépatite B, Infections à VIH.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- Adulte, Adulte d'âge moyen, Co-infection, Facteurs temps, Femelle, Foie, Ghana, Humains, Hépatite B, Infections à VIH, Mâle, Numération des lymphocytes CD4.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active (adverse effects), CD4 Lymphocyte Count, Coinfection, Female, Ghana, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (immunology), Hepatitis B (complications), Hepatitis B (immunology), Humans, Liver (drug effects), Male, Middle Aged, Time Factors.
- MESH :
- chemical , adverse effects : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- geographic : Ghana.
- adverse effects : Antiretroviral Therapy, Highly Active.
- complications : HIV Infections, Hepatitis B.
- drug effects : Liver.
- drug therapy : HIV Infections.
- immunology : HIV Infections, Hepatitis B.
- Adult, CD4 Lymphocyte Count, Coinfection, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes.
DOI: 10.1016/j.jinf.2014.06.012
PubMed: 24975175
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000091
Links to Exploration step
pubmed:24975175Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.</title><author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Kasim, Adetayo" sort="Kasim, Adetayo" uniqKey="Kasim A" first="Adetayo" last="Kasim">Adetayo Kasim</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees TS17 6BH, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees TS17 6BH</wicri:regionArea></affiliation></author><author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Global Health, University of Liverpool, L69 7BE, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Global Health, University of Liverpool, L69 7BE</wicri:regionArea></affiliation></author><author><name sortKey="Chadwick, David R" sort="Chadwick, David R" uniqKey="Chadwick D" first="David R" last="Chadwick">David R. Chadwick</name><affiliation wicri:level="1"><nlm:affiliation>The James Cook University Hospital, Middlesbrough, TS4 3BW, UK. Electronic address: davidr.chadwick@stees.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The James Cook University Hospital, Middlesbrough, TS4 3BW</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24975175</idno><idno type="pmid">24975175</idno><idno type="doi">10.1016/j.jinf.2014.06.012</idno><idno type="wicri:Area/PubMed/Corpus">000091</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000091</idno><idno type="wicri:Area/PubMed/Curation">000091</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000091</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.</title><author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Kasim, Adetayo" sort="Kasim, Adetayo" uniqKey="Kasim A" first="Adetayo" last="Kasim">Adetayo Kasim</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees TS17 6BH, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees TS17 6BH</wicri:regionArea></affiliation></author><author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Global Health, University of Liverpool, L69 7BE, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Global Health, University of Liverpool, L69 7BE</wicri:regionArea></affiliation></author><author><name sortKey="Chadwick, David R" sort="Chadwick, David R" uniqKey="Chadwick D" first="David R" last="Chadwick">David R. Chadwick</name><affiliation wicri:level="1"><nlm:affiliation>The James Cook University Hospital, Middlesbrough, TS4 3BW, UK. Electronic address: davidr.chadwick@stees.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The James Cook University Hospital, Middlesbrough, TS4 3BW</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Journal of infection</title><idno type="eISSN">1532-2742</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (adverse effects)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active (adverse effects)</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Female</term><term>Ghana</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>Hepatitis B (complications)</term><term>Hepatitis B (immunology)</term><term>Humans</term><term>Liver (drug effects)</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (effets indésirables)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Co-infection</term><term>Facteurs temps</term><term>Femelle</term><term>Foie ()</term><term>Ghana</term><term>Humains</term><term>Hépatite B ()</term><term>Hépatite B (immunologie)</term><term>Infections à VIH ()</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Thérapie antirétrovirale hautement active (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Thérapie antirétrovirale hautement active</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hépatite B</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Co-infection</term><term>Facteurs temps</term><term>Femelle</term><term>Foie</term><term>Ghana</term><term>Humains</term><term>Hépatite B</term><term>Infections à VIH</term><term>Mâle</term><term>Numération des lymphocytes CD4</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24975175</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>13</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J. Infect.</ISOAbbreviation></Journal><ArticleTitle>Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.</ArticleTitle><Pagination><MedlinePgn>481-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2014.06.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(14)00190-X</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03-1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR 1.99 (1.16-3.40) on survival analysis. There was no significant difference in CD4 responses between HBsAg-positive and HBsAg-negative patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HBsAg-positive patients are at significantly increased risk of adverse clinical outcomes after starting ART. Further studies are warranted to evaluate whether these risks remain now that tenofovir is becoming routinely available in Ghana.</AbstractText><CopyrightInformation>Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarfo</LastName><ForeName>Fred Stephen</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasim</LastName><ForeName>Adetayo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees TS17 6BH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geretti</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Global Health, University of Liverpool, L69 7BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadwick</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>The James Cook University Hospital, Middlesbrough, TS4 3BW, UK. Electronic address: davidr.chadwick@stees.nhs.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MRC_MR/J01477X/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="Y">Antiretroviral Therapy, Highly Active</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">Clinical outcomes</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Hepatitis B</Keyword><Keyword MajorTopicYN="N">Lamivudine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24975175</ArticleId><ArticleId IdType="pii">S0163-4453(14)00190-X</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2014.06.012</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000091 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000091 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24975175
|texte= Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24975175" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |